Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P42702
UPID:
LIFR_HUMAN
Alternative names:
-
Alternative UPACC:
P42702; Q6LCD9
Background:
The Leukemia inhibitory factor receptor (LIFR) plays a pivotal role as a signal-transducing molecule, intricately involved in the regulation of cellular responses to leukemia inhibitory factor (LIF). Its interaction with the IL6ST pathway underscores its significance in cellular signaling networks. The soluble form of LIFR acts as a natural antagonist, modulating LIF's biological activity by preventing its interaction with cellular receptors.
Therapeutic significance:
LIFR's association with Stuve-Wiedemann syndrome 1, a genetic condition marked by skeletal abnormalities and early infant mortality, highlights its clinical relevance. Understanding the role of Leukemia inhibitory factor receptor could open doors to potential therapeutic strategies for this syndrome and related disorders.